​IDERA PHARMACEUTICALS REPORTS PROMISING DATA FROM ONGOING PHASE 1 DOSE ESCALATION IN CLINICAL TRIAL OF INTRA-TUMORAL IMO-2125 IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH PD-1 REFRACTORY METASTATIC MELANOMA

- 3 Patients with PD-1 Refractory Cutaneous Melanoma are Responders Including One Complete Response (CR) – - Driven by Increased Prioritization of IMO-2125 Clinical Development, Company Suspends Development of IMO-8400 for B-Cell Lymphomas – CAMBRIDGE, Mass & EXTON, Pa, Sept 27 (Bernama-GLOBE NEWSWIRE) --Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing Toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, is reporting initial clinical data from its ongoing Phase 1/2 clinical trial of intra-tumoral IMO-2125, a Toll-like receptor (TLR) 9 agonist.  In this arm of the Phase 1 portion of the trial, IMO-2125 is being evaluated in combination with ipilimumab for treatment of patients with metastatic melanoma who have failed prior PD-1 therapy.  These early results indicate that IMO-2125 is demonstrating promising clinical activity and is being well tolerated in a patient population with minimal options and low expectation of clinical response with ipilimumab treatment alone.  Further clinical information from the ongoing dose escalation portion of the trial, as well as detailed information on the translational results, will be presented during an oral session at the 2016 Society for Immunotherapy of Cancer Annual Meeting beginning November 9th in Maryland. “We have completed extensive pre-clinical work in a broad scope of tumor types to test the hypothesis of intra-tumoral administration of IMO-2125 inducing a meaningful effect on the tumor microenvironment and potentiating local and systemic tumor regression in patients.  This work gave us confidence to test the ability of IMO-2125, beginning with this current study in PD-1 refractory metastatic melanoma patients,” stated Vincent Milano, Idera’s Chief Executive Officer.   http://mrem.bernama.com/viewsm.php?idm=27605